Juvion’s vision is to redefine aging biology. We aim to prove that age-related loss of movement and memory is driven by weakening cell communication in the nervous system, and that it can be restored with the right compounds. Our focus is strengthening neuron-to-muscle signaling for mobility and neuron-to-neuron signaling for memory and cognition. We are building a high-throughput in vivo discovery system powered by machine vision and real aging biology data, enabling rapid testing of hundreads of compounds and deep real time tracking across life stages. Our core models and assays remain fully protected, ensuring a unique and defensible class of Juvion compounds. Juvion001 is our first step toward therapies that restore strength, mobility, and preserve memory.
12.09.2025
Three Swiss startups selected for the Digital Health Accelerator (startupticker.ch)
30.06.2025
Venture Leaders Biotech 2025 connects Swiss science with the US biotech market (venturelab.swiss)
02.06.2025
MassChallenge Switzerland presents 2025 cohort (startupticker.ch)
12.05.2025
Juvion Health Sciences: The Venture Leader Biotech shaping aging therapeutics (venturelab.swiss)
06.05.2025
Venture Leaders Biotech 2025 kick off at Swiss Biotech Day ahead of Boston roadshow (venturelab.swiss)
02.05.2025
Manufacturing JUV-001 for Pilot market entry
15.04.2025
Preclinical validation and toxicology analysis
04.12.2024
Transformation of the Juvion platform into a fully automated system – Transition from academia to industry level.
14.11.2024
Identification of first lead compound-JUV-001
25.10.2024
Innosuisse initial coaching
No Jobs
No videos and documents
Website:
juvionls.com
Headquarter:
Lausanne
Foundation Date:
July 2024
Technology:
Sectors: